About 8,590,000 results
Any time 
Open links in new tab
Gilead taps Korea's Yuhan to supply HIV drug ingredients in $81M …
WEB1 day ago · The deal amount represents 5.8% of Yuhan’s latest yearly sales of 1.85 trillion Korean won ($1.4 billion), according to a filing. Yuhan co-promotes several Gilead HIV …
Yuhan inks $80.9M deal with Gilead Sciences for HIV drug …
WEB2 days ago · Yuhan has secured an $80.9 million deal with California-based Gilead Sciences to supply pharmaceutical ingredients for the treatment of human …
Yuhan inks $81 mn contract with U.S. Gilead to supply …
WEB2 days ago · South Korean pharmaceutical company Yuhan Corp. announced on Friday that it has signed a contract with U.S. biopharmaceutical company Gilead Sciences Inc. to supply raw …
Yuhan Shares Jump 4% After US FDA Approves Anti-Cancer Drug …
WEBAug 21, 2024 · Yuhan Corporation's Equity Buyback Plan Extended till July 31, 2024. -- Shares of Yuhan jumped more than 4% in recent trade after the U.S. Food and Drug …
Yuhan eyes next Leclaza with R&D, open innovation after U.S.
WEBAug 23, 2024 · Following the U.S. approval of lung treatment Leclaza, Korea’s first cancer drug to achieve the milestone, Yuhan Corporation is now seeking the next breakthrough …
Yuhan nabs Ubix cancer drug for ₩150B; YH-35995 trial cleared
WEBJul 1, 2024 · Yuhan Corp., of Seoul, South Korea, has inked a ₩150 billion (US$108.6 million) deal with Korean biotech Ubix Therapeutics Inc. to gain exclusive global rights to …
- People also ask
Yuhan Corporation and J INTS BIO inked a licensing …
WEBSEOUL, South Korea, May 31, 2023 /PRNewswire/ -- Yuhan Corporation (CEO, Wook-Je Cho) announced on the 30th of May that it has signed an in-license agreement with J INTS BIO (CEO, Anna Jo) for a...
Yuhan makes $325M cancer bet to challenge Boehringer, Takeda
WEBMay 31, 2023 · Yuhan Corporation has bought its way into a cancer space targeted by Boehringer Ingelheim and Takeda, wagering up to $325 million to get its hands on a …
Yuhan to pay ₩208B for Cyrus-Kanaph’s SOS1 inhibitor …
WEBMar 8, 2024 · Yuhan Corp., of Seoul, South Korea, added a new potential cancer drug to its oncology pipeline, licensing a son of sevenless homolog 1 (SOS1) inhibitor co-developed by Cyrus Therapeutics Inc. and Kanaph …
Gilead Sciences and Yuhan Corporation Announce Collaboration …
WEBJan 6, 2019 · Yuhan and Gilead will jointly conduct preclinical research, and Gilead will be responsible for global clinical development. Gilead will also be responsible for …
